PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Authors :: Hannah Buckley
Heather Poad
Thomas Powles
Paul Nathan
Helen Howard
G. Carr
Fiona Collinson
Naveen S. Vasudev
Julia Brown
Galina Velikova
Sarah Brown
Gemma Ainsworth
Rosamonde E. Banks
J.M.G. Larkin
Source :: Annals of Oncology. 29:viii331
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: medicine.medical_specialty
business.industry
Urology
Ipilimumab
Hematology
medicine.disease
First line treatment
Oncology
Renal cell carcinoma
medicine
Prism
Nivolumab
business
medicine.drug

Full Text Access

Tools